Kymera Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kymera Therapeutics (KYMR).

Price Target Range — 11 Quarters

Analyst Consensus — 25 Analysts

22Buy

3Hold

Consensus RatingBuy# Analysts25Avg. Consensus PT$119Upside to Avg. PT-6.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 2, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$139→$170
Oct 30, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$136→$150
Oct 30, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$112→$116
Oct 29, 2026	BTIG	Jeet Mukherjee	PT Raise	Buy	$134→$139
Oct 27, 2026	Morgan Stanley	James Quigley	PT Raise	Overweight	$135→$146
Oct 9, 2026	Raymond James	Thomas Deal	Initiate	Outperform	$140
Oct 5, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$135→$150
Sep 22, 2026	Stifel	Alex Thompson	PT Raise	Buy	$132→$152
Sep 14, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$123→$144
Sep 10, 2026	Wolfe Research	Andy Chen	Upgrade	Peer Perform→Outperform	—
Aug 31, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$135→$170
Aug 27, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$116→$151
Aug 6, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$133→$139
Jul 30, 2026	Deutsche Bank	David Hoang	Initiate	Hold	$120
Jul 28, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$125→$135
Jul 16, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$120→$140
Jul 13, 2026	RBC Capital	Brian Abrahams	Downgrade	Outperform→Sector Perform	$106→$115
Jun 30, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$110→$125
Jun 29, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$116→$136
Jun 29, 2026	B. Riley Securities	Kalpit Patel	PT Raise	Buy	$117→$155

Analyst Ratings News

PRO
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170

Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $139 to $170.

Benzinga Newsdesk

PRO
Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150

Truist Securities analyst Srikripa Devarakonda reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $136 to $150.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116

RBC Capital analyst Brian Abrahams maintains Kymera Therapeutics (NASDAQ:KYMR) with a Sector Perform and raises the price target from $112 to $116.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139

BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $134 to $139.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146

Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $135 to $146.

Benzinga Newsdesk

This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Analysts initiate coverage: Outperform on American Express and Kymera, Overweight on Kratos, Hold on IBM and Neutral on Duos.

Avi Kapoor

Kymera Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Kymera Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170

PRO
Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150

PRO
RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116

PRO
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139

PRO
Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146

This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

People Also Watch

People Also Watch

Kymera Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Kymera Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170

PROTruist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150

PRORBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116

PROBTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139

PROMorgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146

This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

People Also Watch

People Also Watch

PRO
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170

PRO
Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150

PRO
RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116

PRO
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139

PRO
Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146